Effects of purified recombinant human interleukin-3 on the growth of human hematopoietic progenitor cells in "long-term" bone marrow culture.

G. Hangoc, Hal Broxmeyer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recombinant human interleukin-3 (rhuIL-3) was assessed for its effects on the growth of normal human hematopoietic bone marrow nucleated cells, and on granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells in a liquid culture system which allows for the prolonged growth of these cells in vitro. RhuIL-3, at concentrations of 100 and 500 units/mL, significantly enhanced the numbers of nucleated cells, as well as the numbers of supernatant and adherent CFU-GM and BFU-E growing in tissue culture flasks or dishes over a period of 4 to 6 weeks. The results demonstrated the rhuIL-3 has a stimulating effect on the growth of human marrow cells in prolonged culture. This information is consistent with the effects of rhuIL-3 in short-term marrow colony assays in vitro and with the in vivo actions of recombinant murine IL-3 in mice, and may be of relevance to clinical trials that will be assessing the hematopoietic effects of rhuIL-3 in humans.

Original languageEnglish
Pages (from-to)17-29
Number of pages13
JournalBiotechnology therapeutics
Volume1
Issue number1
StatePublished - 1989

Fingerprint

Interleukin-3
Hematopoietic Stem Cells
Bone Marrow
Growth
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
Granulocytes
Bone Marrow Cells
Stem Cells
Cell Count
Macrophages
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{0727b05387af412f87b2ca6dec33dff4,
title = "Effects of purified recombinant human interleukin-3 on the growth of human hematopoietic progenitor cells in {"}long-term{"} bone marrow culture.",
abstract = "Recombinant human interleukin-3 (rhuIL-3) was assessed for its effects on the growth of normal human hematopoietic bone marrow nucleated cells, and on granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells in a liquid culture system which allows for the prolonged growth of these cells in vitro. RhuIL-3, at concentrations of 100 and 500 units/mL, significantly enhanced the numbers of nucleated cells, as well as the numbers of supernatant and adherent CFU-GM and BFU-E growing in tissue culture flasks or dishes over a period of 4 to 6 weeks. The results demonstrated the rhuIL-3 has a stimulating effect on the growth of human marrow cells in prolonged culture. This information is consistent with the effects of rhuIL-3 in short-term marrow colony assays in vitro and with the in vivo actions of recombinant murine IL-3 in mice, and may be of relevance to clinical trials that will be assessing the hematopoietic effects of rhuIL-3 in humans.",
author = "G. Hangoc and Hal Broxmeyer",
year = "1989",
language = "English",
volume = "1",
pages = "17--29",
journal = "Biotechnology therapeutics",
issn = "0898-2848",
number = "1",

}

TY - JOUR

T1 - Effects of purified recombinant human interleukin-3 on the growth of human hematopoietic progenitor cells in "long-term" bone marrow culture.

AU - Hangoc, G.

AU - Broxmeyer, Hal

PY - 1989

Y1 - 1989

N2 - Recombinant human interleukin-3 (rhuIL-3) was assessed for its effects on the growth of normal human hematopoietic bone marrow nucleated cells, and on granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells in a liquid culture system which allows for the prolonged growth of these cells in vitro. RhuIL-3, at concentrations of 100 and 500 units/mL, significantly enhanced the numbers of nucleated cells, as well as the numbers of supernatant and adherent CFU-GM and BFU-E growing in tissue culture flasks or dishes over a period of 4 to 6 weeks. The results demonstrated the rhuIL-3 has a stimulating effect on the growth of human marrow cells in prolonged culture. This information is consistent with the effects of rhuIL-3 in short-term marrow colony assays in vitro and with the in vivo actions of recombinant murine IL-3 in mice, and may be of relevance to clinical trials that will be assessing the hematopoietic effects of rhuIL-3 in humans.

AB - Recombinant human interleukin-3 (rhuIL-3) was assessed for its effects on the growth of normal human hematopoietic bone marrow nucleated cells, and on granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells in a liquid culture system which allows for the prolonged growth of these cells in vitro. RhuIL-3, at concentrations of 100 and 500 units/mL, significantly enhanced the numbers of nucleated cells, as well as the numbers of supernatant and adherent CFU-GM and BFU-E growing in tissue culture flasks or dishes over a period of 4 to 6 weeks. The results demonstrated the rhuIL-3 has a stimulating effect on the growth of human marrow cells in prolonged culture. This information is consistent with the effects of rhuIL-3 in short-term marrow colony assays in vitro and with the in vivo actions of recombinant murine IL-3 in mice, and may be of relevance to clinical trials that will be assessing the hematopoietic effects of rhuIL-3 in humans.

UR - http://www.scopus.com/inward/record.url?scp=0024858279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024858279&partnerID=8YFLogxK

M3 - Article

C2 - 2562641

AN - SCOPUS:0024858279

VL - 1

SP - 17

EP - 29

JO - Biotechnology therapeutics

JF - Biotechnology therapeutics

SN - 0898-2848

IS - 1

ER -